
#HEALTH: Do you really need antibiotics for a sore throat?
This issue is particularly evident in the treatment of sore throats, which are usually the result of viral infections and do not require antibiotics.
The widespread overprescription of these medications has serious and extensive consequences, leading to a troubling increase in antibiotic-resistant superbugs that pose a significant threat to public health, says Universiti Sains Malaysia senior consultant, department of otorhinolaryngology - head and neck surgery, Professor Dr Baharudin Abdullah.
The misuse of antibiotics can lead to a rise in mortality rates and exerts a significant burden on healthcare infrastructure and the economy, draining resources and complicating treatment efforts across the board.
"It is more critical than ever to enhance public awareness and promote responsible prescription practices to protect public health and ensure the continued effectiveness of existing antibiotics," says Dr Baharudin.
The World Health Organisation's Global Antimicrobial Resistance and Use Surveillance System has categorised Malaysia as a high-alert nation due to the increasing threat of antimicrobial resistance (AMR).
In comparison to other Asian countries, Malaysia is among the leading nations in terms of antibiotic overuse, akin to Thailand and China, where obtaining antibiotics without a prescription remains a prevalent issue.
The Health Ministry has consistently raised alarms about the escalating issue of AMR, yet the trend of overprescribing antibiotics remains prevalent due to several key factors.
IN DEMAND
Many Malaysians mistakenly believe antibiotics can cure viral infections, and even think they are effective for pain relief.
Many physicians in both public and private primary care settings are often influenced by patient expectations and diagnostic uncertainty, leading to the prescription of antibiotics even when they are not clinically indicated.
Studies show that in Malaysian hospitals, the challenge of AMR is becoming increasingly apparent, with a surge in drug-resistant strains like Methicillin-resistant Staphylococcus aureus and Carbapenem-resistant Enterobacteriaceae.
Dr Baharudin says this predicament results in extended hospital stays, increased healthcare expenses and a greater chance of treatment failures.
"Treating a resistant infection can be up to three times more expensive than a non-resistant one, placing a substantial financial burden on both patients and the healthcare system."
THE ECONOMIC IMPACT
In addition to its effects on healthcare, AMR has major economic and environmental consequences.
According to World Bank estimates, by 2050, AMR may cause the world economy to contract by as much as 3.8 per cent, which might result in the poverty of 28 million people.
The need for more costly second-line therapies and extended hospital stays will drive up prices for the already overburdened healthcare system.
Furthermore, the environmental impact is too great to overlook because overprescribed antibiotics frequently end up in wastewater, contaminating soil and rivers and facilitating the spread of antibiotic resistance in bacterial populations outside of hospital settings.
While the statistics paint a grim picture, Malaysia is not without recourse. The country has already made significant strides in public health, from implementing national antibiotic stewardship programmes to conducting public awareness campaigns.
However, these efforts need to be scaled up and reinforced with a long-term, multi-sectoral approach, says Dr Baharudin.
"Strengthening enforcement of antibiotic sales, improving diagnostic capabilities in primary care settings, and fostering stronger collaboration between healthcare providers, policymakers and the public are critical next steps."
Malaysia has a strong track record of advancing healthcare, which puts it in a unique position to lead efforts domestically and throughout Southeast Asia in the regional fight against AMR, he explains.
Since Malaysia has already made great progress in improving healthcare - from bolstering universal healthcare laws to spearheading programmes for managing infectious diseases - it can support a regional AMR action plan that unites Asean countries in concerted efforts to stop antibiotic abuse.
By advocating for stricter cross-border regulations on antibiotic sales, harmonising prescription guidelines and championing large-scale public awareness campaigns, Malaysia can set the benchmark for responsible antibiotic stewardship in Southeast Asia.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Star
7 hours ago
- The Star
Hepatitis C treatment can be safely shortened
A new clinical trial conducted in Malaysia has found that an eight-week regimen of ravidasvir and sofosbuvir is just as safe and effective as the standard 12-week treatment for chronic hepatitis C. This finding could accelerate efforts to scale up access to treatment in resource-limited settings by reducing treatment duration, costs and system burden. The EASE study (Evaluating Accelerated Shortened treatment for hepatitis C in Asia through real-world Evidence) was led by the Health Ministry (MOH) and conducted across 26 sites nationwide between March 2021 and March 2023. The randomised trial involved 322 patients diagnosed with chronic hepatitis C virus infection, including those with more complex medical profiles. The primary objective was to determine whether an eight-week treatment course using the fixed-dose combination of ravidasvir and sofosbuvir would achieve similar sustained virological response (SVR), compared to the standard 12-week regimen. An SVR refers to the continued absence of the hepatitis C virus in a patient's blood 12 weeks or more after they have completed treatment. It is essentially considered a virological cure for the infection. The study found no significant difference in efficacy between the two durations, with high SVR rates maintained in both arms. Safety profiles were also comparable, with no new adverse effects identified. The results were officially reported by the MOH in January (2025) and presented at the 2025 European Association for the Study of the Liver (EASL) Congress in early May in Amsterdam, the Netherlands. Ravidasvir was co-developed through a public-health partnership involving the MOH, Drugs for Neglected Diseases initiative (DNDi), Pharco Pharmaceuticals (Egypt) and Pharmaniaga Berhad (Malaysia), with key clinical trials conducted in Malaysia and Thailand. The treatment was first registered in Malaysia in 2021 and added to the World Health Organization (WHO) Essential Medicines List in 2023. While hepatitis C continues to affect approximately 50 million people globally, with only about 20% receiving treatment, high drug prices remain a barrier in many countries. A 2023 MOH study estimates 0.4% of the population in Malaysia to have hepatitis C. In line with WHO targets, Malaysia aims to eliminate the disease as a public health threat by 2030.


New Straits Times
13 hours ago
- New Straits Times
IHW 2025 generates RM96mil in sales for Malaysian healthcare firms
KUALA LUMPUR: Malaysian healthcare companies recorded RM96.18 million in sales during the International Healthcare Week (IHW) 2025, held from July 16 to 18 at the Malaysia International Trade and Exhibition Centre (Mitec). The event was organised by UK-based event organiser Informa Markets in strategic partnership with the Malaysia External Trade Development Corporation (Matrade) and featured over 800 exhibitors and attracted more than 22,000 trade visitors. In a statement today, Matrade said the Malaysia Healthcare Day Forum, held during IHW 2025, brought together various ministries and agencies to showcase the country's healthcare ecosystem, highlighting strengths in medical tourism, pharmaceuticals, regulatory standards, and digital health. The event was officiated by Minister of Investment, Trade and Industry, Tengku Datuk Seri Zafrul Abdul Aziz, and also present were Matrade chairman Datuk Seri Reezal Merican Naina Merican and Informa Markets in Asia president and chief executive officer Margaret Ma. Matrade said that 10 Malaysian companies participated under the Malaysia Pavilion, coordinated by the agency, showcasing products ranging from regenerative therapies and diagnostics to wellness supplements and medical disposables. "They successfully generated RM96.18 million in sales, underscoring the event's impact as a high-value platform for international trade and strategic business partnerships in the healthcare sector," it said. Reezal Merican said the initiative has progressed steadily since initial engagements last year, including the inaugural IHW held in Bangkok, driven by ongoing cooperation and development. "Hosting IHW 2025 in Kuala Lumpur marks a transformative leap, as it is not only the largest healthcare trade event in Southeast Asia but also reflects Malaysia's rising stature as a regional healthcare hub," he said. Matrade said that Malaysia's medical device exports grew by 31.6 per cent in 2024 to RM37.03 billion, while pharmaceutical exports increased by four per cent to RM3.04 billion, with key export destinations including the United States, Belgium, Singapore, Germany, and Japan. IHW 2025 also featured four co-located exhibitions, namely CPHI Southeast Asia, WHX Kuala Lumpur, WHX Labs, and Medtec Southeast Asia, along with the Healthcare Information and Management Systems Society (HIMSS) Asia Pacific Conference. A total of 125 conference sessions were held during IHW 2025, focusing on topics such as artificial intelligence in healthcare, pharmaceutical developments, and digital transformation.


The Sun
17 hours ago
- The Sun
Melaka strengthens healthcare with RM150k for health programmes
MELAKA: The Melaka government is committed to maintaining a responsive and comprehensive healthcare ecosystem, said Chief Minister Datuk Seri Ab Rauf Yusoh. He said the commitment includes safeguarding the welfare of all frontliners who form the backbone of public well-being. 'As part of ongoing support for improving healthcare services, the state government has allocated RM150,000 specifically for the implementation of health programmes at the state level. 'This initiative also supports the Agenda Nasional Malaysia Sihat (ANMS) for the benefit of the people in the state,' he said at the appreciation and recognition ceremony for Melaka health workers here last night. Also present were state Health, Human Resource and Unity Committee chairman Datuk Ngwe Hee Sem and Health Ministry secretary-general Datuk Seri Suriani Ahmad. Ab Rauf said that as a proactive measure to strengthen the grassroots healthcare network, Melaka has produced a total of 1,369 community paramedic (Parakom) volunteers in collaboration with the Melaka Health Department and St John Ambulance. He added that in efforts to strengthen the state's healthcare ecosystem, the federal government continues to be attentive to the needs and challenges faced by the sector in Melaka. 'For example, the federal government has approved an allocation of RM45.49 million to upgrade healthcare facilities involving 34 health clinics, seven dental clinics, three rural clinics and three hospitals. 'In addition, Melaka will soon have a military hospital worth RM325 million, which is expected to be completed in January 2029 and will have a significant impact on the state's healthcare sector,' he said. A total of 2,000 healthcare workers from various schemes under the state Health Department, as well as staff from four private hospitals in the state, were honoured at the dinner event. - Bernama